Feasibility study of a hyperspectral imaging system in detection of human skin perfusion and oxygenation - HCS-perfusion

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

October 1, 2019

Last Updated

2 years ago

Study Type

Interventional

Sponsor

•\- Healthy volunteers, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history,
•\- Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight of 50 kg.

•\- History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder.
•\- Systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg.
•\- Use of any medications (prescription or over\-the\-counter \[OTC]), vitamin, mineral, herbal, and dietary supplements within 21 days of study drug administration, or less than 5 half\-lives (whichever is longer). Exceptions are paracetamol (up to 4 g/day). Other exceptions will only be made if the rationale is discussed and clearly documented between the Investigator and the sponsor.
•\- Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
•\- Smokers as defined by any of the following criteria:Reported smoking of cigarettes within 12 months prior to screening; occasionally a cigarette is allowed, but not within 24 hours of the measurements.
•\- Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non\-active hay fever is acceptable).